Aprea AB has raised €46 million in a Series B equity financing co-led by Versant Ventures and 5AM Ventures. The privately-held Swedish company is developing a small molecule drug that reactivates a tumour suppressor protein known as p53.
Scancell Holdings Plc is planning to raise £6.8 million in a two-part equity offering to finance further development of its anti-cancer vaccines. The UK company, which is listed on the AIM market of the London Stock Exchange, has made arrangements to place £3 million of its shares with institutions.
Autolus Ltd, a spin-out from University College London (UCL) that is developing engineered T cell therapies for cancer, has raised £40 million in a Series B financing round bringing total commitments to date from private investors to £70 million.
A new oncology joint venture has been set up in the UK to exploit the gene editing capabilities of Horizon Discovery Group Plc and aptamer technology developed in the US and owned by Centauri Therapeutics Ltd, a UK anti-infectives company.
NeuroVive Pharmaceutical AB, a Swedish biotech specialising in mitochondria protection, is planning to raise SEK 94.4 million (€10.14 million) to finance completion of two Phase 2 studies for its kidney and brain injury compounds.
Privately-owned Akarna Therapeutics Ltd has raised $15 million in a Series B financing round to advance a preclinical drug for non-alcoholic steatohepatitis (NASH), a fatty-liver disease that is associated with both diabetes and obesity.
Sweden-based Redwood Pharma AB has raised SEK 6.6 million (€710,000) in a private equity placement to fund the development of a new hydrogel product for chronic dry eye disease in post-menopausal women.
UK-based Oxford BioMedica Plc is raising £8.1 million with a fully underwritten share placement to finance the expansion of its lentiviral vector manufacturing capacity and advance the clinical development of its gene therapy portfolio.
Shield Therapeutics Plc has raised £32.5 million in an initial public offering of shares on the AIM market of the London Stock Exchange in the wake of a positive opinion from the European Medicines Agency for its drug for iron deficiency anaemia.
Imperial Innovations Group Plc has led a £5 million Series A funding round for the Cambridge University spin-out Aqdot Ltd, a specialist chemical company that has developed a chemical encapsulation technology for use in consumer products.